{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:46:49Z","timestamp":1777448809657,"version":"3.51.4"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1-EY024484-06"],"award-info":[{"award-number":["RO1-EY024484-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-EY030283\u201301"],"award-info":[{"award-number":["R01-EY030283\u201301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R41AI149916-01"],"award-info":[{"award-number":["R41AI149916-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Graft versus host disease (GVHD) is initiated by donor allo-reactive T cells activated against recipient antigens. Chronic GVHD (cGVHD) is characterized by immune responses that may resemble autoimmune features present in the scleroderma and Sjogren\u2019s syndrome. Unfortunately, ocular involvement occurs in approximately 60\u201390% of patients with cGVHD following allo-hematopoietic stem cell transplants (aHSCT). Ocular GVHD (oGVHD) may affect vision due to ocular adnexa damage leading to dry eye and keratopathy. Several other compartments including the skin are major targets of GVHD effector pathways. Using mouse aHSCT models, the objective was to characterize cGVHD associated alterations in the eye and skin to assess for correlations between these two organs. The examination of multiple models of MHC-matched and MHC-mismatched aHSCT identified a correlation between ocular and cutaneous involvement accompanying cGVHD. Studies detected a \u201cpositive\u201d correlation, i.e., when cGVHD-induced ocular alterations were observed, cutaneous compartment alterations were also observed. When no or minimal ocular signs were detected, no or minimal skin changes were observed. In total, these findings suggest underlying cGVHD-inducing pathological immune mechanisms may be shared between the eye and skin. Based on the present observations, we posit that when skin involvement is present in aHSCT patients with cGVHD, the evaluation of the ocular surface by an ophthalmologist could potentially be of value.<\/jats:p>","DOI":"10.3390\/ijms23010184","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T01:00:54Z","timestamp":1640566854000},"page":"184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease"],"prefix":"10.3390","volume":"23","author":[{"given":"Robert B.","family":"Levy","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem M.","family":"Mousa","sequence":"additional","affiliation":[{"name":"School of Medicine, Duke University, Durham, NC 27708, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey O.","family":"Lightbourn","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-1321","authenticated-orcid":false,"given":"Eric J.","family":"Shiuey","sequence":"additional","affiliation":[{"name":"School of Medicine, Duke University, Durham, NC 27708, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Latoni","sequence":"additional","affiliation":[{"name":"School of Medicine, Duke University, Durham, NC 27708, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Duffort","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Flynn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Barreras","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-3170","authenticated-orcid":false,"given":"Michael","family":"Zaiken","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Paz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-9841","authenticated-orcid":false,"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[{"name":"School of Medicine, Duke University, Durham, NC 27708, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri3226","article-title":"Emerging concepts in haematopoietic cell transplantation","volume":"12","author":"Li","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5045\/kjh.2011.46.3.153","article-title":"Treatment of chronic graft-versus-host disease: Past, present and future","volume":"46","author":"Martin","year":"2011","journal-title":"Korean J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12026-013-8450-7","article-title":"The allure and peril of hematopoietic stem cell transplantation: Overcoming immune challenges to improve success","volume":"57","author":"Newman","year":"2013","journal-title":"Immunol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/ICU.0b013e32833eab64","article-title":"Current insights into ocular graft-versus-host disease","volume":"21","author":"Riemens","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/ACI.0b013e328357b4b9","article-title":"Ocular graft-versus-host disease","volume":"12","author":"Hessen","year":"2012","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.ophtha.2009.04.054","article-title":"Ocular Findings after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"116","author":"Tabbara","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archopht.1983.01040010580010","article-title":"The Eye in Bone Marrow Transplantation. I. Clinical study","volume":"101","author":"Hirst","year":"1983","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0161-6420(83)34604-2","article-title":"Ocular Manifestations of Graft-vs-Host Disease","volume":"90","author":"Franklin","year":"1983","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/bmt.2015.187","article-title":"Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation","volume":"50","author":"Na","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.mehy.2003.12.025","article-title":"Sj\u00f6gren\u2019s syndrome: A condition with features of chronic graft-versus-host disease: Does duct cell adhesion or permeability play a role in pathogenesis?","volume":"62","author":"Lamey","year":"2004","journal-title":"Med. Hypotheses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V93.1.66","article-title":"Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease","volume":"93","author":"Marcellus","year":"1999","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1167\/iovs.14-15630","article-title":"Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants","volume":"56","author":"Herretes","year":"2015","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2016.07.012","article-title":"Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model","volume":"22","author":"Perez","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bbmt.2010.08.008","article-title":"Limbus Damage in Ocular Graft-versus-Host Disease","volume":"17","author":"Flores","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","first-page":"598","article-title":"Four cases of corneal perforation in patients with chronic graft-versus-host disease","volume":"17","author":"Inagaki","year":"2011","journal-title":"Mol. Vis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.icu.0000233952.09595.d8","article-title":"Update on ocular graft versus host disease","volume":"17","author":"Kim","year":"2006","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ICO.0b013e318226bf97","article-title":"Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the German\u2013Austrian\u2013Swiss Consensus Conference on Clinical Practice in Chronic GVHD","volume":"31","author":"Cursiefen","year":"2012","journal-title":"Cornea"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wolf, D., Bader, C.S., Barreras, H., Copsel, S., Pfeiffer, B.J., Lightbourn, C.O., Altman, N.H., Komanduri, K.V., and Levy, R.B. (2018). Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. JCI Insight, 3.","DOI":"10.1172\/jci.insight.121717"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2017.02.013","article-title":"Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation","volume":"23","author":"Wolf","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"636789","DOI":"10.3389\/fimmu.2021.636789","article-title":"Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection","volume":"12","author":"Lightbourn","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4049\/jimmunol.0903006","article-title":"STAT3 Signaling in CD4+T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model","volume":"184","author":"Radojcic","year":"2010","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease","volume":"112","author":"Anderson","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.bbmt.2018.04.026","article-title":"Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation\/Functional Profile and Suppress GVHD in a Preclinical Model","volume":"24","author":"Copsel","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2016-08-686659","article-title":"Mechanistic approaches for the prevention and treatment of chronic GVHD","volume":"129","author":"Cutler","year":"2017","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood-2012-04-424135","article-title":"Correlation between NIH composite skin score, patient-reported skin score, and outcome: Results from the Chronic GVHD Consortium","volume":"120","author":"Jacobsohn","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-type chronic GVHD of the skin: Clinical risk factors, laboratory markers, and burden of disease","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jtct.2021.06.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report","volume":"27","author":"Wolff","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-marrow transplantation (second of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:53:10Z","timestamp":1760169190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/1\/184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23010184"],"URL":"https:\/\/doi.org\/10.3390\/ijms23010184","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]}}}